Upregulated microRNA-429 inhibits the migration of HCC cells by targeting TRAF6 through the NF-κB pathway

Wang,Peng; Cao,Jia; Liu,Shihai; Pan,Huazheng; Liu,Xiangping; Sui,Aihua; Wang,Liping; Yao,Ruyong; Liu,Zimin; Liang,Jun

doi:10.3892/or.2017.5507

Upregulated microRNA-429 inhibits the migration of HCC cells by targeting TRAF6 through the NF-κB pathway

Authors:
- Peng Wang
- Jia Cao
- Shihai Liu
- Huazheng Pan
- Xiangping Liu
- Aihua Sui
- Liping Wang
- Ruyong Yao
- Zimin Liu
- Jun Liang
View Affiliations

Affiliations: Department of Oncology, The Afﬁliated Hospital of Qingdao University, Qingdao, Shandong, P.R. China, Clinical medicine college, Ningxia Medical University, Ningxia, P.R. China, Medical Animal Laboratory, The Afﬁliated Hospital of Qingdao University, Qingdao, Shandong, P.R. China, Department of Clinical Laboratory, The Afﬁliated Hospital of Qingdao University, Qingdao, Shandong, P.R. China, Department of Medical Research Center, The Afﬁliated Hospital of Qingdao University, Qingdao, Shandong, P.R. China, Department of Oncology, Weifang Yidu Central Hospital, Qingzhou, Shandong, P.R. China, Department of Oncology, Peking University International Hospital, Beijing, P.R. China
Published online on: March 15, 2017 https://doi.org/10.3892/or.2017.5507
Pages: 2883-2890

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Increasing evidence indicates that miR-429 is involved in tumor suppression in various human cancers. however, its role in hepatocellular carcinoma (HCC) remains unclear. In the present study, we found that miR-429 was significantly downregulated in HCC tissue samples and cell lines. Upregulation of miR-429 markedly suppressed proliferation and migration of HCC cells. Moreover, we identified TRAF6 as a direct target of miR-429. Downregulation of TRAF6 partially attenuated the oncogenic effect of anti‑miR-429 on HCC cells. Ectopic expression of miR-429 in HCC cells inhibited TCF-4 activity as well as nuclear accumulation of P65 and expression of the NF-κB targets c-Myc and phosphorylation of TAK1. In a nude xenograft model, miR-429 upregulation significantly decreased HCC growth. In conclusion, by targeting TRAF6, miR-429 is downregulated in HCC and inhibits HCC cell proliferation and motility. Our data suggest that miR-429 may serve as a potential anticancer target for the treatment of HCC.

View Figures

View References

1	Siegel RL, Miller KD and Jemal A: Cancer statistics, 2015. CA Cancer J Clin. 65:5–29. 2015. View Article : Google Scholar : PubMed/NCBI
2	Marquardt JU and Thorgeirsson SS: SnapShot: Hepatocellular carcinoma. Cancer Cell. 25:550.e5512014. View Article : Google Scholar
3	Agrawal S, Agarwal S, Arnason T, Saini S and Belghiti J: Management of hepatocellular adenoma: Recent advances. Clin Gastroenterol Hepatol. 13:1221–1230. 2015. View Article : Google Scholar : PubMed/NCBI
4	Mehlen P and Puisieux A: Metastasis: A question of life or death. Nat Rev Cancer. 6:449–458. 2006. View Article : Google Scholar : PubMed/NCBI
5	Shenouda SK and Alahari SK: MicroRNA function in cancer: Oncogene or a tumor suppressor? Cancer Metastasis Rev. 28:369–378. 2009. View Article : Google Scholar : PubMed/NCBI
6	Oishi N, Yamashita T and Kaneko S: Molecular biology of liver cancer stem cells. Liver Cancer. 3:71–84. 2014. View Article : Google Scholar : PubMed/NCBI
7	Bandiera S, Pfeffer S, Baumert TF and Zeisel MB: miR-122 - a key factor and therapeutic target in liver disease. J Hepatol. 62:448–457. 2015. View Article : Google Scholar : PubMed/NCBI
8	Kota J, Chivukula RR, ODonnell KA, Wentzel EA, Montgomery CL, Hwang HW, Chang TC, Vivekanandan P, Torbenson M, Clark KR, et al: Therapeutic microRNA delivery suppresses tumorigenesis in a murine liver cancer model. Cell. 137:1005–1017. 2009. View Article : Google Scholar : PubMed/NCBI
9	Lee CH, Kim JH and Lee SW: The role of microRNAs in hepatitis C virus replication and related liver diseases. J Microbiol. 52:445–451. 2014. View Article : Google Scholar : PubMed/NCBI
10	Yuan Q, Loya K, Rani B, Möbus S, Balakrishnan A, Lamle J, Cathomen T, Vogel A, Manns MP, Ott M, et al: MicroRNA-221 overexpression accelerates hepatocyte proliferation during liver regeneration. Hepatology. 57:299–310. 2013. View Article : Google Scholar : PubMed/NCBI
11	Huang JY, Zhang K, Chen DQ, Chen J, Feng B, Song H, Chen Y, Zhu Z, Lu L, De W, et al: MicroRNA-451: Epithelial-mesenchymal transition inhibitor and prognostic biomarker of hepatocelluar carcinoma. Oncotarget. 6:18613–18630. 2015. View Article : Google Scholar : PubMed/NCBI
12	Zheng Z, Liu J, Yang Z, Wu L, Xie H, Jiang C, Lin B, Chen T, Xing C, Liu Z, et al: MicroRNA-452 promotes stem-like cells of hepatocellular carcinoma by inhibiting Sox7 involving Wnt/β-catenin signaling pathway. Oncotarget. 7:28000–28012. 2016.PubMed/NCBI
13	Tan G, Wu L, Tan J, Zhang B, Tai WC, Xiong S, Chen W, Yang J and Li H: MiR-1180 promotes apoptotic resistance to human hepatocellular carcinoma via activation of NF-κB signaling pathway. Sci Rep. 6:223282016. View Article : Google Scholar : PubMed/NCBI
14	Hall DP, Cost NG, Hegde S, Kellner E, Mikhaylova O, Stratton Y, Ehmer B, Abplanalp WA, Pandey R, Biesiada J, et al: TRPM3 and miR-204 establish a regulatory circuit that controls oncogenic autophagy in clear cell renal cell carcinoma. Cancer Cell. 26:738–753. 2014. View Article : Google Scholar : PubMed/NCBI
15	Cheng CJ, Bahal R, Babar IA, Pincus Z, Barrera F, Liu C, Svoronos A, Braddock DT, Glazer PM, Engelman DM, et al: MicroRNA silencing for cancer therapy targeted to the tumour microenvironment. Nature. 518:107–110. 2015. View Article : Google Scholar : PubMed/NCBI
16	Zhang M, Dong BB, Lu M, Zheng MJ, Chen H, Ding JZ, Xu AM and Xu YH: miR-429 functions as a tumor suppressor by targeting FSCN1 in gastric cancer cells. Onco Targets Ther. 9:1123–1133. 2016.PubMed/NCBI
17	Wu CL, Ho JY, Chou SC and Yu DS: MiR-429 reverses epithelial-mesenchymal transition by restoring E-cadherin expression in bladder cancer. Oncotarget. 7:26593–26603. 2016.PubMed/NCBI
18	Ye ZB, Ma G, Zhao YH, Xiao Y, Zhan Y, Jing C, Gao K, Liu ZH and Yu SJ: miR-429 inhibits migration and invasion of breast cancer cells in vitro. Int J Oncol. 46:531–538. 2015.PubMed/NCBI
19	Chen W, Zhang B, Guo W, Gao L, Shi L, Li H, Lu S, Liu Y and Li X: miR-429 inhibits glioma invasion through BMK1 suppression. J Neurooncol. 125:43–54. 2015. View Article : Google Scholar : PubMed/NCBI
20	Sun Y, Shen S, Liu X, Tang H, Wang Z, Yu Z, Li X and Wu M: MiR-429 inhibits cells growth and invasion and regulates EMT-related marker genes by targeting Onecut2 in colorectal carcinoma. Mol Cell Biochem. 390:19–30. 2014. View Article : Google Scholar : PubMed/NCBI
21	Lei W, Liu YE, Zheng Y and Qu L: MiR-429 inhibits oral squamous cell carcinoma growth by targeting ZEB1. Med Sci Monit. 21:383–389. 2015. View Article : Google Scholar : PubMed/NCBI
22	Lang Y, Xu S, Ma J, Wu J, Jin S, Cao S and Yu Y: MicroRNA-429 induces tumorigenesis of human non-small cell lung cancer cells and targets multiple tumor suppressor genes. Biochem Biophys Res Commun. 450:154–159. 2014. View Article : Google Scholar : PubMed/NCBI
23	Tang J, Li L, Huang W, Sui C, Yang Y, Lin X, Hou G, Chen X, Fu J, Yuan S, et al: MiR-429 increases the metastatic capability of HCC via regulating classic Wnt pathway rather than epithelial-mesenchymal transition. Cancer Lett. 364:33–43. 2015. View Article : Google Scholar : PubMed/NCBI
24	Li L, Tang J, Zhang B, Yang W, LiuGao M, Wang R, Tan Y, Fan J, Chang Y, Fu J, et al: Epigenetic modification of MiR-429 promotes liver tumour-initiating cell properties by targeting Rb binding protein 4. Gut. 64:156–167. 2015. View Article : Google Scholar : PubMed/NCBI
25	Gao H and Liu C: miR-429 represses cell proliferation and induces apoptosis in HBV-related HCC. Biomed Pharmacother. 68:943–949. 2014. View Article : Google Scholar : PubMed/NCBI
26	Bradley JR and Pober JS: Tumor necrosis factor receptor-associated factors (TRAFs). Oncogene. 20:6482–6491. 2001. View Article : Google Scholar : PubMed/NCBI
27	Chung JY, Park YC, Ye H and Wu H: All TRAFs are not created equal: Common and distinct molecular mechanisms of TRAF-mediated signal transduction. J Cell Sci. 115:679–688. 2002.PubMed/NCBI
28	Peng Z, Shuangzhu Y, Yongjie J, Xinjun Z and Ying L: TNF receptor-associated factor 6 regulates proliferation, apoptosis, and invasion of glioma cells. Mol Cell Biochem. 377:87–96. 2013. View Article : Google Scholar : PubMed/NCBI
29	He Z, Huang C, Lin G and Ye Y: siRNA-induced TRAF6 knockdown promotes the apoptosis and inhibits the invasion of human lung cancer SPC-A1 cells. Oncol Rep. 35:1933–1940. 2016.PubMed/NCBI
30	Lin D, Zhang M, Zhang MX, Ren Y, Jin J, Zhao Q, Pan Z, Wu M, Shu HB, Dong C, et al: Induction of USP25 by viral infection promotes innate antiviral responses by mediating the stabilization of TRAF3 and TRAF6. Proc Natl Acad Sci USA. 112:11324–11329. 2015. View Article : Google Scholar : PubMed/NCBI
31	Xiao F, Wang H, Fu X, Li Y and Wu Z: TRAF6 promotes myogenic differentiation via the TAK1/p38 mitogen-activated protein kinase and Akt pathways. PLoS One. 7:e340812012. View Article : Google Scholar : PubMed/NCBI
32	Walsh MC, Lee J and Choi Y: Tumor necrosis factor receptor- associated factor 6 (TRAF6) regulation of development, function, and homeostasis of the immune system. Immunol Rev. 266:72–92. 2015. View Article : Google Scholar : PubMed/NCBI
33	Perkins ND: The diverse and complex roles of NF-κB subunits in cancer. Nat Rev Cancer. 12:121–132. 2012.PubMed/NCBI
34	Starczynowski DT, Lockwood WW, Deléhouzée S, Chari R, Wegrzyn J, Fuller M, Tsao MS, Lam S, Gazdar AF, Lam WL, et al: TRAF6 is an amplified oncogene bridging the RAS and NF-κB pathways in human lung cancer. J Clin Invest. 121:4095–4105. 2011. View Article : Google Scholar : PubMed/NCBI